You have free access to this content

Cancer

Cover image for Vol. 116 Issue 17

1 September 2010

Volume 116, Issue 17

Pages 3983–4213

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Commentaries

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    1. You have free access to this content
      The integrity of authorship : Doing the right thing (pages 3986–3987)

      Raphael E. Pollock and Michael S. Ewer

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25268

      Conflicts of interest with regard to peer-reviewed publications are a matter of increasing concern. The authors examined the balance between industry support of a publication and the integrity of authorship.

  3. Review Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    1. You have free access to this content
      Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas (pages 3988–3999)

      Marc C. Chamberlain

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25256

      • original image
      • original image

      Bevacizumab, a vascular endothelial growth factor antibody, has been granted US Food and Drug Administration approval as a single agent for the treatment of previously treated glioblastoma and is associated with manageable, class-specific toxicity. In this review, the author summarizes the clinical efficacy and safety data on bevacizumab in high-grade gliomas, practical issues regarding its administration, and ongoing investigations in additional brain tumor treatment settings.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Review Articles
    5. Original Articles
    1. Disease Site

      Breast Disease
      You have free access to this content
      Population-based analysis of occult primary breast cancer with axillary lymph node metastasis (pages 4000–4006)

      Gary V. Walker, Grace L. Smith, George H. Perkins, Julia L. Oh, Wendy Woodward, Tse-Kuan Yu, Kelly K. Hunt, Karen Hoffman, Eric A. Strom and Thomas A. Buchholz

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25197

      • original image
      • original image
      • original image

      A population-based analysis using the Surveillance, Epidemiology, and End Results database was conducted to assess practice patterns and outcomes in patients with occult primary breast cancer and axillary lymph node metastasis. Definitive locoregional treatment with either mastectomy or breast-conserving therapy improved the outcome of patients with this presentation, and no difference was observed between the treatments.

    2. Melanoma
      You have free access to this content
      Prognostic factors derived from a prospective database dictate clinical biology of anal cancer : The intergroup trial (RTOG 98-11) (pages 4007–4013)

      Jaffer A. Ajani, Kathryn A. Winter, Leonard L. Gunderson, John Pedersen, Al B. Benson III, Charles R. Thomas Jr, Robert J. Mayer, Michael G. Haddock, Tyvin A. Rich and Christopher G. Willett

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25188

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      A total of 644 prospectively treated patients with anal carcinoma were analyzed to derive prognostic factors. The resulting data establish tumor diameter as an independent prognosticator of poorer disease-free survival (DFS) and overall survival (OS) and confirm clinically positive nodes and male sex as poor prognostic factors. This analysis also uncovers novel subgroups (derived from combining prognostic factors) with incremental worsening of DFS and OS.

    3. Gastrointestinal Disease
      You have free access to this content
      Increased exposure to bacterial antigen RpL7/L12 in early stage colorectal cancer patients (pages 4014–4022)

      Annemarie Boleij, Rian Roelofs, Renée M. J. Schaeps, Tanja Schülin, Philippe Glaser, Dorine W. Swinkels, Ikuko Kato and Harold Tjalsma

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25212

      • original image
      • original image
      • original image
      • original image

      The humoral immune response to bacterial antigen RpL7/L12 is significantly increased in early stage colorectal cancer patients. This provides clinical support for the hypothesis that certain intestinal bacteria constitute a risk factor for the progression of premalignant lesions into early stage carcinomas

    4. You have free access to this content
      Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer (pages 4023–4032)

      Jennifer J. Knox, Rebecca Wong, Antonio L. Visbal, Anne M. Horgan, Maha Guindi, Jennifer Hornby, Wei Xu, Jolie Ringash, Shaf Keshavjee, Eric Chen, Masoom Haider and Gail Darling

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25349

      • original image
      • original image
      • original image
      • original image
      • original image

      This phase 2 trial assessed the feasibility and efficacy of trimodality therapy for esophageal cancer patients. Induction irinotecan/cisplatin chemotherapy concurrent with radiotherapy followed by esophagectomy was associated with an early improvement in dysphagia, a significant but manageable toxicity profile, and encouraging survival compared with historic controls.

    5. Discipline

      Translational Research
      You have free access to this content
      Epigenetic and genetic silencing of CHFR in esophageal adenocarcinomas (pages 4033–4042)

      Mohammed Soutto, DunFa Peng, Mohammad Razvi, Petra Ruemmele, Arndt Hartmann, Albert Roessner, Regine Schneider-Stock and Wael El-Rifai

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25151

      • original image
      • original image
      • original image
      • original image
      • original image

      The checkpoint with forkhead-associated domain and RING-finger domain (CHFR) is a mitotic checkpoint protein with tumor-suppressor functions. The authors demonstrate that both epigenetic and genetic mechanisms are involved in silencing CHFR expression in esophageal adenocarcinomas.

    6. Disease Site

      Gynecologic Oncology
      You have free access to this content
      A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer (pages 4043–4053)

      Fang Fang, Curt Balch, Jeanne Schilder, Timothy Breen, Shu Zhang, Changyu Shen, Lang Li, Carol Kulesavage, Anthony J. Snyder, Kenneth P. Nephew and Daniela E. Matei

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25204

      • original image
      • original image
      • original image
      • original image
      • original image

      Based on preclinical studies indicating that hypomethylating agents can reverse platinum resistance in ovarian cancer, this phase 1 trial tested low-dose decitabine combined with carboplatin in patients with recurrent, platinum-resistant ovarian cancer. This combination was well tolerated and induced biological activity (DNA hypomethylation), supporting further testing in ovarian cancer.

    7. Hematologic Malignancies
      You have free access to this content
      Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas : Results of a randomized trial (pages 4054–4062)

      Nina Arakelyan, Jean-Philippe Jais, Vincent Delwail, Josette Brière, Marie-Pierre Moles-Moreau, Delphine Sénécal, Christian Berthou, Bernard Desablens, Pierre Colonna, Jean-Marie Andrieu and on behalf of the GOELAMS Hodgkin Lymphoma Network

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25295

      • original image
      • original image
      • original image
      • original image

      The randomized H97-E trial was designed in 1997 to assess the impact of a slightly reduced, tailored, extended irradiation dose after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine. This treatment did not have an impact on the excellent cure rate among patients with early Hodgkin lymphoma but significantly reduced the rate of 10-year radiation-induced complications.

    8. You have free access to this content
      Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome (pages 4063–4068)

      Amit Lahoti, Hagop Kantarjian, Abdulla K. Salahudeen, Farhad Ravandi, Jorge E. Cortes, Stefan Faderl, Susan O'Brien, William Wierda and Gloria N. Mattiuzzi

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25306

      • original image

      Relatively mild elevations in creatinine are associated with higher mortality in patients with acute leukemia. Strategies to avoid nephrotoxic drugs or fluid overload may be of benefit.

    9. Lung Disease
      You have free access to this content
      Intra-arterial iodine-131-lipiodol for unresectable hepatocellular carcinoma (pages 4069–4077)

      Terence C. Chua, Francis Chu, S. Patrick Butler, Richard J. Quinn, Derek Glenn, Winston Liauw and David L. Morris

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25283

      • original image
      • original image
      • original image

      Iodine-131-Lipiodol is an appropriate palliative treatment, with encouraging survival outcomes for patients with unresectable exclusively intrahepatic hepatocellular carcinoma. Its best achieved therapeutic effect is in patients with multiple small tumors.

    10. You have free access to this content
      Clonal origin of multifocal hepatocellular carcinoma (pages 4078–4085)

      Kurt B. Hodges, Oscar W. Cummings, Romil Saxena, Mingsheng Wang, Shaobo Zhang, Antonio Lopez-Beltran, Rodolfo Montironi, Hammam Nour and Liang Cheng

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25258

      • original image
      • original image

      The majority of patients with multifocal hepatocellular carcinomas have common clonal origin. A better understanding of the genetic relationships between multiple tumors may be clinically important in assessing prognosis and selecting therapeutic options in these patients.

    11. Discipline

      Clinical Trials
      You have free access to this content
      A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver (pages 4086–4094)

      Apostolia M. Tsimberidou, Siqing Fu, Chaan Ng, Jo Ann Lim, Sijin Wen, David Hong, Jennifer Wheler, Agop Y. Bedikian, Cathy Eng, Michael Wallace, Luis H. Camacho and Razelle Kurzrock

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25277

      • original image
      • original image

      The authors conducted a phase 1 safety/dose-finding study of hepatic arterial infusion (HAI) oxaliplatin combination therapy in patients with advanced cancer and liver metastases. HAI oxaliplatin combined with systemic 5-fluorouracil, leucovorin, and bevacizumab had antitumor activity in patients with advanced cancer and liver metastases and appeared to warrant further study.

    12. Disease Site

      Lung Disease
      You have free access to this content
      Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer (pages 4095–4102)

      Jared D. Christensen, Tom V. Colby and Edward F. Patz Jr

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25302

      • original image
      • original image
      • original image

      Stage I nonsmall cell lung cancers are histologically heterogeneous, comprised of many cell types, including tumor and inflammatory cells. However, there appears to be no statistically significant correlation between a specific tumor cellular component and [18F]-2-fluoro-deoxy-D-glucose (FDG) activity.

    13. You have free access to this content
      Relationship between cytokine gene single nucleotide polymorphisms and symptom burden and quality of life in lung cancer survivors (pages 4103–4113)

      Sarah M. Rausch, Matthew M. Clark, Christi Patten, Heshan Liu, Sara Felten, Yafei Li, Jeff Sloan and Ping Yang

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25255

      The goal of this study was to examine whether cytokine gene single nucleotide polymorphisms (SNPs) were associated with quality of life (QOL) and symptom burden in a large sample of Caucasian lung cancer survivors. Significant associations were found with cytokine gene SNPs and pain, fatigue, appetite, dyspnea, hemoptysis, and QOL.

    14. You have free access to this content
      Elevated pretreatment serum concentration of YKL-40—An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer (pages 4114–4121)

      Ina Thöm, Birte Andritzky, Gunter Schuch, Iris Burkholder, Lutz Edler, Julia S. Johansen, Carsten Bokemeyer, Udo Schumacher and Eckart Laack

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25196

      • original image
      • original image

      In this study, pretreatment serum levels of the glycoprotein YKL-40 were determined in 189 patients who had metastatic nonsmall cell lung cancer (NSCLC). The YKL-40 serum level was identified as a new independent prognostic biomarker in patients with metastatic NSCLC.

    15. Melanoma
      You have free access to this content
      Bevacizumab and everolimus in the treatment of patients with metastatic melanoma : A phase 2 trial of the Sarah Cannon Oncology Research Consortium (pages 4122–4129)

      John D. Hainsworth, Jeffrey R. Infante, David R. Spigel, James D. Peyton, Dana S. Thompson, Cassie M. Lane, Bobby L. Clark, Mark S. Rubin, David F. Trent and Howard A. Burris III

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25320

      • original image
      • original image
      • original image

      This phase 2 trial evaluated the activity and tolerability of the combination of the antiangiogenic agent bevacizumab with the mammalian target of rapamycin (mTOR) inhibitor everolimus in the treatment of patients with metastatic melanoma. Although the combination was found to have moderate activity (median progression-free survival and overall survival of 4 months and 8.6 months, respectively) and was generally well tolerated in these patients, future therapy using bevacizumab and everolimus may be improved by the incorporation of agents that inhibit the mitogen-activated protein kinase (MAPK) pathway.

    16. You have free access to this content
      Prognostic factors in cutaneous desmoplastic melanoma : A study of 252 patients (pages 4130–4138)

      Rajmohan Murali, Helen M. Shaw, Kenneth Lai, Stanley W. McCarthy, Michael J. Quinn, Jonathan R. Stretch, John F. Thompson and Richard A. Scolyer

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25148

      • original image
      • original image
      • original image

      The authors investigated important prognostic factors in patients with clinically localized, primary, cutaneous desmoplastic melanoma. The sentinel lymph node-positive rate was lower in patients with desmoplastic melanoma than in patients with conventional melanoma. The results indicated that the extent of tumor desmoplasia is associated significantly and independently with the time to recurrence and should be evaluated routinely in patients with desmoplastic melanoma.

    17. You have free access to this content
      High response rate after intratumoral treatment with interleukin-2 : Results from a phase 2 study in 51 patients with metastasized melanoma (pages 4139–4146)

      Benjamin Weide, Evelyna Derhovanessian, Annette Pflugfelder, Thomas K. Eigentler, Peter Radny, Henning Zelba, Claudia Pföhler, Graham Pawelec and Claus Garbe

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25156

      • original image
      • original image
      • original image
      • original image
      • original image

      Interleukin-2 (IL-2) was injected intratumorally into metastases and elicited complete local responses in 69% of patients with melanoma. In addition, survival rates were high, indicating a possible systemic mode of action for locally applied IL-2.

    18. Discipline

      Pediatric Oncology
      You have free access to this content
      Noninvasive imaging with thallium-201 scintigraphy may not correlate with survival in patients with osteosarcoma (pages 4147–4151)

      Heather Magnan, Alexander J. Chou, Joanne F. Chou, Henry W.D. Yeung, John H. Healey and Paul A. Meyers

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25375

      • original image

      Although thallium-201 (T1-201) scintigraphic response to preoperative chemotherapy has previously been shown to correlate with histologic response, in this series of 22 patients with osteosarcoma, Tl-201 scintigraphic response to preoperative chemotherapy did not appear to correlate with event-free survival. It is necessary to use robust outcome variables and not rely on surrogates for outcome to evaluate potential prognostic factors.

    19. Disparities Research
      You have free access to this content
      Ethnic differences in chronic health conditions after hematopoietic cell transplantation : A report from the Bone Marrow Transplant Survivor Study (pages 4152–4159)

      Saro H. Armenian, Can-Lan Sun, Jennifer Berano Teh, Mukta Arora, K. Scott Baker, Liton Francisco, Stephen J. Forman and Smita Bhatia

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25157

      • original image

      In this study, the authors investigated the burden of morbidity in long-term Hispanic survivors of hematopoietic stem cell transplantation (HCT) compared with their white, non-Hispanic counterparts and examined the role of sociodemographic factors to explain the observed differences. The results indicated that Hispanics are less likely to report severe/life-threatening health conditions after HCT than white non-Hispanics—a difference that decreased in magnitude and significance after taking health insurance into consideration.

    20. You have free access to this content
      The impact of socioeconomic status on stage of cancer at diagnosis and survival : A population-based study in Ontario, Canada (pages 4160–4167)

      Christopher M. Booth, Gavin Li, Jina Zhang-Salomons and William J. Mackillop

      Version of Record online: 2 AUG 2010 | DOI: 10.1002/cncr.25427

      • original image

      Despite universal healthcare, SES remains associated with survival among patients with cancer in Ontario. Disparities in outcome are not explained by differences in stage of cancer at time of diagnosis.

    21. You have free access to this content
      Pathologic complete response in breast cancer patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy : Evaluating the effect of race/ethnicity (pages 4168–4177)

      Mariana Chavez-MacGregor, Jennifer Litton, Huiqin Chen, Sharon H. Giordano, Clifford A. Hudis, Antonio C. Wolff, Vicente Valero, Gabriel N. Hortobagyi, Melissa L. Bondy and Ana Maria Gonzalez-Angulo

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25296

      • original image
      • original image

      Among 2074 breast cancer patients treated with anthracycline- and taxane-based neoadjuvant chemotherapy, race/ethnicity was not found to be significantly associated with pathologic complete response rates. Improved outcomes were observed in Hispanics and a trend toward worse outcomes in black patients, when compared with whites.

    22. You have free access to this content
      Insurance status and survival disparities among nonelderly rectal cancer patients in the National Cancer Data Base (pages 4178–4186)

      Anthony S. Robbins, Amy Y. Chen, Andrew K. Stewart, Charles A. Staley, Katherine S. Virgo and Elizabeth M. Ward

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25317

      After adjustment for age, further adjustment for 9 other factors reduced the excess mortality among rectal cancer patients without private insurance by approximately 70%. Disparities in stage and treatment accounted for approximately 53% of the excess mortality, whereas factors other than stage and treatment accounted for approximately 17%.

    23. Epidemiology
      You have free access to this content
      Neighborhood socioeconomic status and behavioral pathways to risks of colon and rectal cancer in women (pages 4187–4196)

      Daniel Kim, Katherine E. Masyn, Ichiro Kawachi, Francine Laden and Graham A. Colditz

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25195

      • original image
      • original image

      Living in a richer neighborhood may protect against rectal cancer in women and colon cancer in higher-educated women. These associations may be mediated by behavioral risk factors including body mass index.

    24. Pediatric Oncology
      You have free access to this content
      Risk factors for central venous catheter thrombotic complications in children and adolescents with cancer (pages 4197–4205)

      S. Revel-Vilk, J. Yacobovich, H. Tamary, G. Goldstein, S. Nemet, M. Weintraub, O. Paltiel and G. Kenet

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25199

      • original image
      • original image
      • original image

      Both patient-related and central venous catheter (CVC)-related factors are associated with higher risk of symptomatic CVC occlusion and thrombosis. The results of this study could help physicians, nurses and families in the decision process involved in choosing the type of central venous line to be inserted and could be used to develop future studies for reducing the rate of CVC-related complications.

    25. Disease Site

      Head and Neck Disease
      You have free access to this content
      Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy (pages 4206–4213)

      Voichita Bar Ad, Gregory Weinstein, Pinaki R. Dutta, Arie Dosoretz, Ara Chalian, Stefan Both and Harry Quon

      Version of Record online: 19 AUG 2010 | DOI: 10.1002/cncr.25274

      • original image

      Gabapentin was examined as possible therapy for pain in patients with head and neck malignancies treated with concurrent chemoradiotherapy. Gabapentin appeared promising in reducing the need for high total doses of narcotic pain medication and reducing unplanned treatment interruptions.

SEARCH

SEARCH BY CITATION